(Q45711137)

15 December 2017

title

Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis (English)

1 reference

15 December 2017

1 reference

1 reference

Jens Neumann

1

1 reference

15 December 2017

Laura Wehweck

2

1 reference

15 December 2017

Susanne Maatz

3

1 reference

15 December 2017

Jutta Engel

4

1 reference

15 December 2017

Thomas Kirchner

5

1 reference

15 December 2017

Andreas Jung

6

1 reference

15 December 2017

publication date

10 August 2013

1 reference

15 December 2017

1 reference

15 December 2017

volume

463

1 reference

15 December 2017

issue

4

1 reference

15 December 2017

page(s)

509-523

1 reference

https://scigraph.springernature.com/pub.10.1007/s00428-013-1450-0

15 December 2017

exact match

0 references

cites work

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

EGFR Signaling in Colorectal Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

HER2 testing in gastric cancer: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Evolution of intratumoral genetic heterogeneity during colorectal cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1450-0

Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents

21 January 2018

1 reference

12 December 2020

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

1 reference

12 December 2020

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases

1 reference

12 December 2020

Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type

1 reference

12 December 2020

Molecular genetics of colorectal cancer

1 reference

12 December 2020

Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy

1 reference

12 December 2020

Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis

1 reference

12 December 2020

Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality

1 reference

12 December 2020

Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes.

1 reference

12 December 2020

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

1 reference

12 December 2020

10.1007/S00428-013-1450-0

Identifiers

DOI

1 reference

Dimensions Publication ID

15 December 2017

1042809798

0 references

1 reference